文献速递流行病学与生物统计真实世界研究与卫生经济

美国癌症相关静脉血栓栓塞症患者华法林与直接口服抗凝药生存结局比较:基于人群的队列研究

Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.
PubMed 文献 · PLoS Med · 2022-05-25

基于美国SEER-Medicare数据库2012至2016年数据,分析胃癌、结直肠癌、胰腺癌、肺癌、卵巢癌或脑癌合并静脉血栓栓塞症(VTE)患者接受直接口服抗凝药(DOAC)或华法林治疗后的总生存期。中位随访41个月,华法林组中位总生存期12.0个月(95%CI 10.9–13.5)优于DOAC组9.9个月(95%CI 8.4–11.2),HR 0.85(95%CI 0.78–0.91;p<0.001)。

要点

  • 在癌症相关VTE患者中,华法林组中位总生存期12.0个月,DOAC组为9.9个月。
  • 华法林较DOAC与更长的总生存期相关(HR 0.85;95%CI 0.78–0.91;p<0.001)。
  • 生存差异在癌症部位、分期和VTE类型各亚组中一致。

核心结论

  • 在基于人群的注册分析中,华法林较DOAC与癌症相关VTE患者更长的总生存期相关。

研究设计与样本

  • 利用美国SEER-Medicare链接数据库2012至2016年数据,纳入诊断胃癌、结直肠癌、胰腺癌、肺癌、卵巢癌或脑癌并在VTE诊断30天内接受DOAC或华法林处方的患者。
  • 通过癌症分期的精确匹配和年龄、癌症部位、癌症分期、癌症至VTE诊断时间间隔的倾向评分匹配,按DOAC与华法林1:2匹配。
  • 共分析4,274例患者,DOAC组1,348例,华法林组2,926例;中位年龄75岁,女性占56%。

主要发现

  • DOAC组中1,188例(88%)使用利伐沙班,160例(12%)使用阿哌沙班。
  • 中位随访41个月,华法林组中位总生存期12.0个月(95%CI 10.9–13.5)vs DOAC组9.9个月(95%CI 8.4–11.2),HR 0.85(95%CI 0.78–0.91;p<0.001)。
  • 生存差异在癌症部位、癌症分期和VTE类型各亚组中一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究为回顾性设计,可能存在未计入的混杂因素。
  • 研究结果在所研究的癌症诊断之外的普遍性存在问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct oral anticoagulants (DOACs) have comparable efficacy with low-molecular-weight heparin (LMWH) for the treatment of cancer-associated venous thromboembolism (VTE). Whether there is a mortality benefit of DOACs compared with warfarin in the management of VTE in cancer is not established. METHODS AND FINDINGS: Utilizing the United States' Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases from 2012 through 2016, we analyzed overall survival in individuals diagnosed with a primary gastric, colorectal, pancreas, lung, ovarian, or brain cancer and VTE who received a prescription of DOAC or warfarin within 30 days of VTE diagnosis. Patients were matched 1:2 (DOAC to warfarin) through exact matching for cancer stage and propensity score matching for age, cancer site, cancer stage, and time interval from cancer to VTE diagnosis. The analysis identified 4,274 patients who received a DOAC or warfarin for the treatment of VTE within 30 days of cancer diagnosis (1,348 in DOAC group and 2,926 in warfarin group). Patients were of median age 75 years and 56% female. Within the DOAC group, 1,188 (88%) received rivaroxaban, and 160 (12%) received apixaban. With a median follow-up of 41 months, warfarin was associated with a statistically significantly higher overall survival compared to DOACs (median overall survival 12.0 months [95% confidence interval (CI): 10.9 to 13.5] versus 9.9 months [95% CI: 8.4 to 11.2]; hazard ratio (HR) 0.85; 95% CI: 0.78 to 0.91; p < 0.001). Observed differences in survival were consistent across subgroups of cancer sites, cancer stages, and type of VTE. The study limitations include retrospective design with potential for unaccounted confounders along with issues of generalizability beyond the cancer diagnoses studied. CONCLUSIONS: In this analysis of a population-based registry, warfarin was associated with prolonged overall survival compared to DOACs for treatment of cancer-associated VTE.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Khan AM, Chiasakul T, Redd R, et al. Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. PLoS Med. 2022. PMID: 35613184. doi:10.1371/journal.pmed.1004012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。